Prostate Cancer: References

Content provided by Healthwise

References

Citations

1. American Cancer Society (2006). Cancer Facts and Figures 2006, pp. 1–56. Atlanta: American Cancer Society. Available online: http://www.cancer.org/docroot/STT/stt_0.asp.

2. Kantoff PW (2002). Prostate cancer. In DC Dale, DD Federman, eds., Scientific American Medicine, section 12, chap. 9. New York: WebMD.

3. Carter HB, Partin AW (2002). Diagnosis and staging of prostate cancer. In PC Walsh et al., eds., Campbell's Urology, 8th ed., vol. 4, pp. 3055–3079. Philadelphia: W.B. Saunders.

4. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361(9360): 859–864.

5. U.S. Preventive Services Task Force (2003). Screening for prostate cancer: Recommendations and rationale. American Family Physician, 67(4): 787–792.

6. Reiter RE, deKernion JB (2002). Epidemiology, etiology, and prevention of prostate cancer. In PC Walsh et al., eds., Campbell's Urology, 8th ed., vol. 4, pp. 3003–3024. Philadelphia: W.B. Saunders.

7. National Cancer Institute (2005). Prostate Cancer (PDQ): Prevention—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/prevention/prostate/HealthProfessional/page3.

8. Bill–Axelson A, et al. (2005). Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 352(19): 1977–1984.

9. Punglia RS, et al. (2003). Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. New England Journal of Medicine, 349(4): 335–342.

10. Scher HI, et al. (2005). Cancer of the prostate. In VT DeVita Jr et al., eds., Cancer: Principles and Practice of Oncology, 7th ed., pp. 1192–1259. Philadelphia: Lippincott Williams and Wilkins.

11. Long JP, et al. (2001). Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology, 57(3): 518–523.

12. Thompson IM, et al. (2003). The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349(3): 213–222.

13. Roberts RO, et al. (2002). A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proceedings, 77(3): 217–218.

14. Schoonen WM, et al. (2005). Alcohol consumption and risk of prostate cancer in middle-aged men. International Journal of Cancer, 113(1): 133–140.

Other Works Consulted

• Carroll PR, et al. (2004). Fourth international conference on innovations and challenges in prostate cancer: Prevention, detection, and treatment. Journal of Urology, 172(5): S3–S5.

• D'Amico AV, et al. (2004). 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer. JAMA, 292(7): 821–827.

• McNeel DG, Malkovsky M (2005). Immune-based therapies for prostate cancer. Immunology Letters, 96(1): 3-9.

• National Comprehensive Cancer Network and the American Cancer Society (2004). Prostate Cancer: Clinical Practice Guidelines in Oncology, version 1.2004. Jenkintown, PA: National Comprehensive Cancer Network.

E-mail This | Print This Previous Chapter | Next Chapter

Last updated:	July 24, 2006
Author:	Ralph Poore
Reviewed By:	Kathleen Romito, MD - Family Medicine, Christopher G. Wood, MD, FACS - Urology/Oncology
Editors:	Renée Spengler, RN, BSN, Terrina Vail